If you are not happy with the results below please do another search
Mergers and acquisitions (M&As) in the biopharmaceutical industry have rebounded with a $76.9 billion increase in total deal value seen from 2022 to 2023. In Q1 2024 alone, biopharmaceutical M&A reached a total deal value of $43.5 billion, with a 71% year-on-year (YoY) increase of mega deals that were valued at $1 billion or more compared to Q1 2023, reveals GlobalData.
In today’s first-quarter 2024 financial results, Bayer reported a slight drop in sales amid its sweeping companywide restructuring that resulted in workforce reductions, while lowering its full-year earnings outlook.
The company announced that the FDA declined to approve the expanded use of its hepatitis B vaccine in patients undergoing hemodialysis, citing insufficient safety and effectiveness data.
Cytokinetics released data on aficamten, an oral small molecule inhibitor of cardiac myosin, showing it significantly boosted exercise capacity in patients with obstructive hypertrophic cardiomyopathy.
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy (semaglutide) provides cardiovascular benefits irrespective of starting weight and the amount of weight lost.
Gilgamesh’s pipeline is powered by its proprietary drug discovery platform, which combines “complex behavioral assessments, advanced electrophysiology and molecular measures of neuroplasticity” to identify and design novel drugs, according to the biotech’s website.
Our team has proactively worked to build strong mutual cultures with dozens of clients over the years, and we’ve distilled our learnings into a recipe that market access teams can easily follow — and enjoy.
The duo making up The Joint Adventure have earned industry-wide acclaim and numerous awards — from Gold and Silver Cannes Lions to Art Directors Club and Clios — for their art direction and copywriting bonafides, respectively.
The new investment will create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company states.
Today the company announced it had discontinued an experimental combination treatment testing a new type of immunotherapy in patients with a severe form of skin cancer after side effects led to high discontinuation.
